Phenotypic Characterization and Prevalence of Carbapenemase-Producing Acinetobacter baumanii Isolates in Four Health Facilities in Cameroon  

作　　者：Cécile Ingrid Djuikoue Benhamed Nadjia Paule Dana Djouela Djoulako Celianthe Guegang Cedric Seugnou Nana Hélène Valérie Same Njanjo Yemina Grace Kombeu Christiane Kiyang Possi Rodrigue Kamga Wouambo Gandhi Ndieffouo Fosso Merimé Joel Tchinda Talokou Bianca Tchounga Chimi Olivier Pomte Agbor Michael Benjamin D. Thumamo Pokam Nicolas Antoine-Moussiaux Cécile Ingrid Djuikoue;Benhamed Nadjia;Paule Dana Djouela Djoulako;Celianthe Guegang;Cedric Seugnou Nana;Hélène Valérie Same Njanjo;Yemina Grace Kombeu;Christiane Kiyang Possi;Rodrigue Kamga Wouambo;Gandhi Ndieffouo Fosso;Merimé Joel Tchinda Talokou;Bianca Tchounga Chimi;Olivier Pomte;Agbor Michael;Benjamin D. Thumamo Pokam;Nicolas Antoine-Moussiaux(Department of Public Health, Faculty of Health Sciences of the Université des Montagnes, Bangangté, Cameroon;American Society for Microbiology, Bangangte, Cameroon;Université des Sciences et de la Technologie d’Oran Mohamed Boudiaf, Oran, Algeria;Faculty of Medicine, Sorbonne Université, Paris, France;Estuary Academic and Strategic Institute (IUEs/INSAM), Douala, Cameroon;Faculty of Medicine and Pharmaceutic Sciences, University of Douala, Douala, Cameroon;Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, University of Leipzig, Leipzig, Germany;Centre Hospitalier Dominicain St Martin de Porres, Yaounde, Cameroon;Department of Medical Laboratory Science, Faculty of Health Sciences, University of Buea, Buea, Cameroon;Faculty of Veterinary Medicine, University of Liège, Liège, Belgium)

机构地区：[1]Department of Public Health, Faculty of Health Sciences of the Université des Montagnes, Bangangté, Cameroon [2]American Society for Microbiology, Bangangte, Cameroon [3]Université des Sciences et de la Technologie d’Oran Mohamed Boudiaf, Oran, Algeria [4]Faculty of Medicine, Sorbonne Université, Paris, France [5]Estuary Academic and Strategic Institute (IUEs/INSAM), Douala, Cameroon [6]Faculty of Medicine and Pharmaceutic Sciences, University of Douala, Douala, Cameroon [7]Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, University of Leipzig, Leipzig, Germany [8]Centre Hospitalier Dominicain St Martin de Porres, Yaounde, Cameroon [9]Department of Medical Laboratory Science, Faculty of Health Sciences, University of Buea, Buea, Cameroon [10]Faculty of Veterinary Medicine, University of Liège, Liège, Belgium

出　　处：《Open Journal of Medical Microbiology》2023年第3期234-249,共16页医学微生物学（英文）

摘　　要：Background and Objective: Nowadays, the clinical utility of carbapenems is threatened by the emergence of resistant bacteria, favored by its increasing use. According to the WHO, Acinetobacter baumannii: nosocomial infection agent, tops the list of priority antibiotic-resistant pathogens, considered to be the riskiest for humans. This study sought to determine the prevalence of carbapenemase-producing Acinetobacter baumannii strains in four health facilities in the Center and Littoral regions of Cameroon and the associated risk factors. Materials and Method: An analytical cross-sectional study was conducted over a six-month period from January to June 2022. All suspicious A. baumanii isolates obtained from pathological samples at the bacteriology laboratory of the different health facilities were systematically collected and re-identified. Re-identification and antimicrobial susceptibility Testing (AST) were performed using the VITEK 2 System and the Kirby-Bauer method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). Detection and phenotypic characterization of carbapenemases was performed according to adequate standard procedures. Results: A total of 168/226 clinical isolates of Acinetobacter baumannii were confirmed after re-identification, among which 52.69% derived from male patients, 55.09% from participants aged between 10 - 39 years old, and 46.71% from pus samples. A very high resistance rates to all families of antibiotics was noted, except to colistin (10.2%). 40.12% of these isolates produced carbapenemase, represented by 62.69% of class B and 37.31% of class A. Carbapenemase production was observed only at HMR1, Centre region and at Laquintinie hospital, Littoral region with 53.33% and 50% respectively, even if there is no significant difference (P = 0.81). In addition, frequent hospitalisation was significantly associated to the production of carbapenemase among A. baumanii (Adjusted-OR = 16.53, P-value 0.0001). Conclusion: This study highlighted the emergence oBackground and Objective: Nowadays, the clinical utility of carbapenems is threatened by the emergence of resistant bacteria, favored by its increasing use. According to the WHO, Acinetobacter baumannii: nosocomial infection agent, tops the list of priority antibiotic-resistant pathogens, considered to be the riskiest for humans. This study sought to determine the prevalence of carbapenemase-producing Acinetobacter baumannii strains in four health facilities in the Center and Littoral regions of Cameroon and the associated risk factors. Materials and Method: An analytical cross-sectional study was conducted over a six-month period from January to June 2022. All suspicious A. baumanii isolates obtained from pathological samples at the bacteriology laboratory of the different health facilities were systematically collected and re-identified. Re-identification and antimicrobial susceptibility Testing (AST) were performed using the VITEK 2 System and the Kirby-Bauer method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). Detection and phenotypic characterization of carbapenemases was performed according to adequate standard procedures. Results: A total of 168/226 clinical isolates of Acinetobacter baumannii were confirmed after re-identification, among which 52.69% derived from male patients, 55.09% from participants aged between 10 - 39 years old, and 46.71% from pus samples. A very high resistance rates to all families of antibiotics was noted, except to colistin (10.2%). 40.12% of these isolates produced carbapenemase, represented by 62.69% of class B and 37.31% of class A. Carbapenemase production was observed only at HMR1, Centre region and at Laquintinie hospital, Littoral region with 53.33% and 50% respectively, even if there is no significant difference (P = 0.81). In addition, frequent hospitalisation was significantly associated to the production of carbapenemase among A. baumanii (Adjusted-OR = 16.53, P-value 0.0001). Conclusion: This study highlighted the emergence o

关 键 词：Acinetobacter baumannii RESISTANCE CARBAPENEMASES Health Facilities 

分 类 号：F42[经济管理—产业经济]